Taiwan Advance Bio-Pharmaceutical Overview
Get informed when a big investor buys or sells
+ Follow41.29
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Taiwan Advance Bio-Pharmaceutical (4186.TWO) currently reports a P/E ratio of 41.29. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Taiwan Advance Bio-Pharmaceutical's P/E ratio history and peer comparisons.
Taiwan Advance Bio-Pharmaceutical's P/E ratio of 41.29 is lower than the Healthcare sector average of 70.94. That is roughly 41.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Taiwan Advance Bio-Pharmaceutical's market price to a fundamental measure such as earnings, sales, or book value. At 41.29, 4186.TWO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 41.29, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Taiwan Advance Bio-Pharmaceutical, and consider following 4186.TWO for alerts when major investors trade the stock.
Taiwan Advance Bio-Pharmaceutical is classified in the Healthcare sector. On P/E ratio, it currently shows 41.29 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4186.TWO with unrelated industries.
